Drug
Mapracorat clinical trials
Also written BOL-303242-X and ZK 245186.
- studies test it
- 13
- open now
- 0
- in phase 3
- 4
- first study started
- 2009
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
13 studies that test it; most in 2011 (5)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 2 |
| 2013 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 7
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Studies
Open first, then newest update. How each study uses mapracorat is read from its arms, and is right about nine times in ten.
Testing it · 13
- HPA Axis Study in AdultsCompletedPhase 2BayerNCT01408511Written as Mapracorat
- HPA Axis Study in Japanese AdultsCompletedPhase 2BayerNCT01407510Written as Mapracorat
- Dose Escalation of Different Concentrations of ZK 245186 in Atopic DermatitisCompletedPhase 2BayerNCT00944632Written as ZK 245186
- Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract SurgeryCompletedPhase 2Bausch & Lomb IncorporatedNCT00905450Written as BOL-303242-X
- Mapracorat Ophthalmic Formulation in Subjects With Allergic ConjunctivitisCompletedPhase 2Bausch & Lomb IncorporatedNCT01289431Written as Mapracorat
- Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryCompletedPhase 3Bausch & Lomb IncorporatedNCT01591655Written as Mapracorat
- Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract SurgeryCompletedPhase 3Bausch & Lomb IncorporatedNCT01230125Written as Mapracorat
- Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryCompletedPhase 3Bausch & Lomb IncorporatedNCT01591161Written as Mapracorat
- Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract SurgeryTerminatedPhase 3Bausch & Lomb IncorporatedNCT01298752Written as Mapracorat
- 1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to MapracoratCompletedPhase 1BayerNCT03399526Written as Mapracorat (ZK 245186, BAY 86-5319)
- Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)CompletedPhase 2BayerNCT01228513Written as ZK245186
- Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)CompletedPhase 2BayerNCT01359787Written as Mapracorat
- Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 DaysCompletedPhase 1Bausch & Lomb IncorporatedNCT01736462Written as Mapracorat
Codes
What other systems call mapracorat · ClinicalTrials.gg INT005556
- UNII (FDA) 145V79YBVPMAPRACORATConfirmed FDA, Wikidata
- Wikidata Q6754194mapracoratConfirmed FDA, Wikidata
- NCI Thesaurus C166458MapracoratOne source FDA
- DrugBank DB12041One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 145V79YBVP | MAPRACORAT | Confirmed FDA, Wikidata |
| Wikidata | Q6754194 | mapracorat | Confirmed FDA, Wikidata |
| NCI Thesaurus | C166458 | Mapracorat | One source FDA |
| DrugBank | DB12041 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.